Pelareorep
From Wikipedia, the free encyclopedia
Pelareorep (previously known under the trademark Reolysin)[1] is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies.[2][3] Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses.[2] Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types (including breast, colorectal and pancreatic, as well as multiple myeloma) when administered alone and in combination with other cancer therapies.[4][5][6][7][8][9][10]
This article is missing information about {{drugbox}} . (July 2021) |
In April 2015, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to pelareorep for malignant glioma.[11] In May 2017, the FDA granted Fast Track Designation for pelareorep in metastatic breast cancer.[12]
Oncolytics Biotech has more than 415 patents for pelareorep issued globally, including more than 60 in the U.S. and 20 in Canada, as well as numerous patents pending worldwide.[13]